https://scholars.lib.ntu.edu.tw/handle/123456789/568483
標題: | IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients | 作者: | Hsu C.-S. SHIH-JER HSU Liu W.-L. CHI-LING CHEN CHUN-JEN LIU PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2013 | 出版社: | International Medical Press Ltd | 卷: | 18 | 期: | 4 | 起(迄)頁: | 599-606 | 來源出版物: | Antiviral Therapy | 摘要: | Background: IL-21R polymorphisms have been identified as potential predictors of virological outcomes in Western chronic hepatitis C (CHC) patients receiving interferonbased treatment. We aimed to examine the associations of IL-21R genotypes and serum IL-21 levels with virological responses to interferon-based treatment in Asian CHC patients. Methods: Genomic and clinical data were collected from 178 consecutive Taiwanese HCV genotype 1 patients who received interferon-based therapy and 72 non-HCV healthy subjects. Among them, serum IL-21 levels, IL-21R and IL-28B genotypes were determined in 124 CHC patients and healthy controls. Results: Among patients with IL28B rs8099917 non-TT genotypes, patients with IL-21R rs3093390 CC genotype had a higher sustained virological response rate than those with non-CC genotypes (CC versus non-CC 14/24 versus 0/4; P=0.031). Compared with non-HCV controls, CHC patients had higher serum IL-21 levels (mean ±sdHCV versus non-HCV 377.8 ±780.9 versus 70.5 ±33.2 pg/ml; P=0.001). Patients with sustained virological response had higher pretreatment serum IL-21 levels than those without (adjusted OR 0.23, 95% CI 0.07, 0.80; P=0.021). Conclusions: CHC patients have higher serum IL-21 levels than healthy adults. Higher pretreatment serum IL-21 levels and IL-21R polymorphisms may serve as potential factors predictive of treatment outcomes in CHC patients with interferon-based therapy. ? 2013 International Medical Press. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885357800&doi=10.3851%2fIMP2502&partnerID=40&md5=21cdf03b388ab6470e7d9ae0e59a6767 https://scholars.lib.ntu.edu.tw/handle/123456789/568483 |
ISSN: | 1359-6535 | DOI: | 10.3851/IMP2502 | SDG/關鍵字: | alanine aminotransferase; alpha interferon; cytosine; interleukin 21; interleukin 21 receptor; interleukin 28B; peginterferon alpha2a; ribavirin; adult; antiviral therapy; article; Asian; controlled study; DNA polymorphism; drug response; female; genetic association; genotype; hepatitis C; human; IL 21R gene; major clinical study; male; outcome assessment; priority journal; protein blood level; Adult; Antiviral Agents; Case-Control Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Prognosis; Receptors, Interleukin-21; Recombinant Proteins; Taiwan; Viral Load |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。